Growth equity fund closes $1.2B Fund IV
Upper-middle-market software and healthcare services focus; first close oversubscribed.
Insights
Market dashboard, investor guides, perspectives, and research — structured for founders, boards, and institutional investors.
Keningford Partners regularly publishes strategic insights on how growth-stage companies access institutional capital and execute transactions. Our research is sector-agnostic by design: it reflects mandate activity across equity, debt, and M&A rather than a single vertical headline cycle. Each report and guide examines a specific corner of the growth-stage capital markets and is written to be useful to founders, boards, investors, and the advisers who sit alongside them.
Featured Booklet · Free Download
How growth-stage equity cycles lengthened, and what founders should do each phase from readiness through close.
Six to twelve months from a growth process? Take the raise readiness diagnostic before you read the full phase map.
Keningford Partners Research
The 14-Week Growth-Round Equity Process Map
18 min read · PDF Booklet
FAQ
Cooley GO’s Quarterly Venture Financing Reports place the median time-to-close for US growth-stage equity rounds at roughly fourteen weeks in H1 2025, against an eight-week median in 2023. Keningford Partners expects the fourteen-to-eighteen-week range to remain the operational base case through 2026 and 2027, because the structural drivers, deeper diligence, larger syndicates, harder term-sheet structure, are not cyclical.
Capital Markets Dashboard
Week of July 7, 2026
Upper-middle-market software and healthcare services focus; first close oversubscribed.
Growth-stage therapeutics and sustainable materials mandate with family office anchor commitments.
Illustrative weekly snapshot for market context, not live market data or investment advice.
Investor Guides
18 min read
How growth-stage equity cycles lengthened, and what founders should do each phase from readiness through close.
10 min read
What family offices weigh beyond headline returns: alignment, governance, liquidity, and relationship quality.
12 min read
How institutional limited partners underwrite emerging and established managers in a selective deployment environment.
11 min read
A practical framework for founders evaluating financing alternatives without defaulting to equity dilution.
13 min read
What institutional investors examine in financial, commercial, and legal diligence, and how to prepare.
11 min read
The elements institutional investors expect in a concise, credible investment memorandum.
Market Insights

Vertical AI has become one of the most contested growth-stage capital destinations. Investors are paying for workflow depth, retention, and defensible data — not model wrappers.

Healthcare AI rounds in 2025–2026 closed at premium multiples relative to horizontal software — but only for assets with reimbursement clarity, clinical validation, and enterprise distribution.

Family offices are redeploying toward direct investments, co-investments, and structured equity — with longer hold periods and sharper governance expectations than the prior cycle.

When equity is expensive, growth-stage founders are rebuilding the capital stack with venture debt, structured credit, and hybrid instruments, without defaulting to dilution.

As the median time from Series A to IPO stretches past a decade, secondary tenders and structured liquidity programs have become a core tool for retention — not a sign of weakness.

Down rounds are no longer exceptional. Founders facing a reset should compare four structural paths — and three questions — before signing terms.
Research
Deal velocity, valuation benchmarks, and capital availability across power, renewables, and midstream assets in North America and the Middle East.
A structured review of raise activity, pricing dynamics, and investor positioning across growth equity, private credit, and structured capital.
How growth-stage biotech and deep-tech companies are positioning for institutional capital across venture crossover, strategic capital, and project finance.
How growth-stage healthcare AI companies are positioning for institutional capital — reimbursement clarity, clinical validation, and enterprise distribution as the new underwriting baseline.
A practical primer on secondary tenders, company-sponsored repurchases, and structured liquidity — when they work, how they are priced, and what boards should prepare.